A report from the US Oncology Network/Ontada revealed that overall, only 75% of patients with triple-negative breast cancer (TNBC) in the United States underwent germline genetic testing. The study findings were presented at the 2023 annual meeting of the American Society of Clinical Oncology (abstract 1094). The study found that rates of testing were even lower in individuals who were Black (67%), had a lower socioeconomic status, or resided in the South and Midwest of the United States.
JULY 21, 2023